Tags

Type your tag names separated by a space and hit enter

Placebo controlled double-blind study of pentoxifylline in sickle cell disease patients.
J Med. 1987; 18(5-6):277-91.JM

Abstract

Sixty patients (37 males, 23 females, age range 7 to 34 years) suffering from sickle cell disease were treated with pentoxifylline (1200 mg/day per os, Trental 400 t.i.d.) or placebo in a double-blind randomized study of six week duration. Observation of pain frequency, intensity and duration of pain events as well as determination of various laboratory and hematologic parameters were maintained on weekly or biweekly basis, respectively, throughout the study. At the end of the trial the number of patients (14) with pain periods and the number of pain events (57) and the mean duration of pain events (4.1 days) in the drug group were significantly better than in the placebo group with 25 patients with pain, 219 pain events and 8.8 days mean pain duration. Hematocrit, red cell count, hemoglobin and platelet aggregation showed slight but significant positive changes with no corresponding alteration with placebo. The over all assessment of the therapeutic response showed 21 clearly improved patients with pentoxifylline compared to 10 such patients with placebo (p less than 0.05). Two patients on pentoxifylline and four on placebo experienced transient side effects of nausea and gastric intolerance.

Authors+Show Affiliations

Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil.

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

3333162

Citation

Manrique, R V.. "Placebo Controlled Double-blind Study of Pentoxifylline in Sickle Cell Disease Patients." Journal of Medicine, vol. 18, no. 5-6, 1987, pp. 277-91.
Manrique RV. Placebo controlled double-blind study of pentoxifylline in sickle cell disease patients. J Med. 1987;18(5-6):277-91.
Manrique, R. V. (1987). Placebo controlled double-blind study of pentoxifylline in sickle cell disease patients. Journal of Medicine, 18(5-6), 277-91.
Manrique RV. Placebo Controlled Double-blind Study of Pentoxifylline in Sickle Cell Disease Patients. J Med. 1987;18(5-6):277-91. PubMed PMID: 3333162.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Placebo controlled double-blind study of pentoxifylline in sickle cell disease patients. A1 - Manrique,R V, PY - 1987/1/1/pubmed PY - 1987/1/1/medline PY - 1987/1/1/entrez SP - 277 EP - 91 JF - Journal of medicine JO - J Med VL - 18 IS - 5-6 N2 - Sixty patients (37 males, 23 females, age range 7 to 34 years) suffering from sickle cell disease were treated with pentoxifylline (1200 mg/day per os, Trental 400 t.i.d.) or placebo in a double-blind randomized study of six week duration. Observation of pain frequency, intensity and duration of pain events as well as determination of various laboratory and hematologic parameters were maintained on weekly or biweekly basis, respectively, throughout the study. At the end of the trial the number of patients (14) with pain periods and the number of pain events (57) and the mean duration of pain events (4.1 days) in the drug group were significantly better than in the placebo group with 25 patients with pain, 219 pain events and 8.8 days mean pain duration. Hematocrit, red cell count, hemoglobin and platelet aggregation showed slight but significant positive changes with no corresponding alteration with placebo. The over all assessment of the therapeutic response showed 21 clearly improved patients with pentoxifylline compared to 10 such patients with placebo (p less than 0.05). Two patients on pentoxifylline and four on placebo experienced transient side effects of nausea and gastric intolerance. SN - 0025-7850 UR - https://www.unboundmedicine.com/medline/citation/3333162/Placebo_controlled_double_blind_study_of_pentoxifylline_in_sickle_cell_disease_patients_ L2 - http://www.diseaseinfosearch.org/result/6589 DB - PRIME DP - Unbound Medicine ER -